Tournament: Holy Cross | Round: 2 | Opponent: L C Anderson AS | Judge: David Herrera
Integration between pharma and biotech is accelerating, unlocking innovation.
Cancherini ’21 Laura; April 30; Consultant in McKinsey’s Brussels office; McKinsey, “What’s ahead for biotech: Another wave or low tide?” https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/whats-ahead-for-biotech-another-wave-or-low-tide
When we asked
AND
of health applications.
IP law restriction bombs innovation; chills RandD and patent stability.
DeRoo 11Pier DeRoo (J.D. Candidate 2011, University of Michigan Law School; A.B. 2006, Chemistry, Princeton University). “Public Non-Commercial Use' Compulsory Licensing for Pharmaceutical Drugs in Go Pharmaceutical Drugs in Government Health Car ernment Health Care Programs.” Michigan Journal of International Law, vol. 32, issue 2. 2011. JDN. https://repository.law.umich.edu/mjil/vol32/iss2/3/
Government health care
AND
unexplored areas of medicine.
Innovation optimizes synthetic biology---extinction.
Karoui et al. ’19 Meriem, Monica Hoyos-Flight, and Liz Fletcher; August 7; Centre for Synthetic and Systems Biology in the School of Biological Sciences at the University of Edinburgh; Innogen Institute in the School of Social and Political Sciences at the University of Edinburgh; Frontiers, “Future Trends in Synthetic Biology—A Report,” https://www.frontiersin.org/articles/10.3389/fbioe.2019.00175/full
Tackling Risk
Synthetic biology is
AND
in synthetic biology